What is Senores Pharmaceuticals Ltd (SENORES) share price return in the past 10 years?

Data is not available for this company

What is the share price of Senores Pharmaceuticals Ltd (SENORES)?

Company share prices are keep on changing according to the market conditions. The current trading price of Senores Pharmaceuticals Ltd (SENORES) on 24-Jun-2026 16:59:59 at 16:59 is 1275.90.

What is the P/E ratio of Senores Pharmaceuticals?

The latest standalone P/E ratio of Senores Pharmaceuticals as of 24-Jun-2026 is 290.17.

What is the P/B ratio of Senores Pharmaceuticals Ltd (SENORES)?

The latest standalone P/B ratio of Senores Pharmaceuticals Ltd (SENORES) as of 24-Jun-2026 is 7.84.

What is the 52-week high and low of Senores Pharmaceuticals Ltd (SENORES)?

The 52-week high of Senores Pharmaceuticals Ltd (SENORES) is Rs. 1355.70 and the 52-week low is Rs. 522.90.

Senores Pharmaceuticals Ltd (SENORES) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Senores Pharmaceuticals Ltd (SENORES)
Brand: Senores Pharmaceuticals

Senores Pharmaceuticals Ltd (SENORES)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544319 NSE: SENORES Pharmaceuticals & Drugs | Small Cap | Senores Pharmaceutic Share Price

Senores Pharmaceuticals Ltd (SENORES)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544319 NSE: SENORES Pharmaceuticals & Drugs | Small Cap | Senores Pharmaceutic Share Price

Key Metrics

Valuation Multiples

Market Cap

₹5,876 Cr.

Current Price

₹1,275.9

52-Week Low / High

₹523 / 1,356

TTM EPS

₹4.4

TTM Sales

₹106 Cr.

Book Value per Share

₹162.8

P/E Ratio

290.17

In line with its 5-year historical median

Industry PE

48.5

Price to Book (P/B)

7.84

Higher than its 5-year historical median

Price to Sales (P/S)

55.39

Lower than its 5-year historical median

EV/EBITDA

121.70

Lower than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

0.84%

Underperforms industry median

Return on Capital Employed (ROCE)

2.19%

Underperforms industry median

Return on Assets (ROA)

0.66%

Operating Profit Margin

-19.1%

Net Profit Margin

9.57%

Gross Profit Margin

21.3%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

13.32%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

355.56%

Asset Quality

Promoter Holding

45.82%

Pledged shares (%) of Promoter's holding (%)

1.90%

Reserves

₹704 Cr.

Equity

₹46.1 Cr.

Face Value

₹10

All Time Low / High

₹440.00 / 1355.70

Senores Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Not Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Senores Pharmaceuticals Ltd a good quality company?

Senores Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Senores Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Senores Pharmaceuticals Ltd vs industry peers?

Senores Pharmaceuticals Ltd revenue CAGR is 41.72%, compared to the industry median CAGR of 6.81%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Senores Pharmaceuticals Ltd?

Promoters hold 45.82% of the Senores Pharmaceuticals Ltd, with 1.90% of their stake pledged, indicating low pledge risk.

Q.1 Stock return of Senores Pharmaceuticals Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of 119.45% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	2.9%	5.5%	2.6%	2.2%	-
Value Creation Index ⓘ	-0.8	-0.6	-0.8	-0.8	-
Growth Parameters ⓘ
Sales ⓘ	13.5	12.4	34	38.5	106
Sales YoY Gr.	-	-8.6%	174.7%	13.3%	-
Adj EPS ⓘ	0.6	-1.2	0.1	0.3	4.4
YoY Gr.	-	-314%	NA	138.5%	-
BVPS (₹) ⓘ	38.5	39.7	55.1	153.7	162.8
Adj Net Profit ⓘ	0.5	-1.2	0.4	1.4	20
Cash Flow from Ops. ⓘ	-24.1	-43.4	-62.8	-20.4	-
Debt/CF from Ops. ⓘ	-0.6	-1.4	-1.5	-4.6	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	NA	41.7%	13.3%
Adj EPS ⓘ	NA	NA	-18.4%	138.5%
BVPSⓘ	NA	NA	58.6%	179%
Share Price	-	-	-	123.3%

Key Financial Parameters ⓘ

	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.5	-3.3	0.4	0.3	2.8
Op. Profit Mgn % ⓘ	8.5	-14.4	-0.2	-19.1	-4.5
Net Profit Mgn % ⓘ	3.7	-9.7	1.1	3.7	19.1
Debt to Equity ⓘ	0.4	1.6	0.6	0.1	0.1
Working Cap Days ⓘ	0	1,783	1,262	2,047	449
Cash Conv. Cycle ⓘ	0	311	157	196	344

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'22	Mar'23	Mar'24	Mar'25
Sales	14	12	34	39
Operating Expenses ⓘ +	12	14	34	46
Manufacturing Costs	0	0	3	5
Material Costs	8	6	19	18
Employee Cost	3	5	9	18
Other Costs ⓘ	1	3	3	4
Operating Profit ⓘ	1	-2	-0	-7
Operating Profit Margin (%)	8.5%	-14.4%	-0.2%	-19.1%
Other Income ⓘ +	1	7	7	22
Exceptional Items ⓘ	0	0	0	0
Interest ⓘ	1	2	3	7
Depreciation ⓘ	1	1	2	3
Profit Before Tax ⓘ	1	2	2	5
Tax ⓘ	0	1	1	1
Profit After Tax	1	1	1	4
PAT Margin (%)	5.0%	9.7%	2.4%	9.6%
Adjusted EPS (₹)	0.8	1.2	0.3	0.8
Dividend Payout Ratio (%)	0%	0%	0%	0%

Valuation of Senores Pharmaceutic - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	34	39	168	708
Share Capital ⓘ	9	10	31	46
Reserves ⓘ	25	29	138	662
Debt +	14	32	28	86
Long Term Debt	12	24	20	76
Short Term Debt	2	8	8	10
Minority Interest	0	0	0	0
Trade Payables	6	4	12	13
Others Liabilities ⓘ	1	36	78	27
Total Liabilities ⓘ	55	112	286	834
Fixed Assets
Net Fixed Assets ⓘ +	2	8	24	55
Gross Block	3	10	28	62
Accumulated Depreciation	1	2	4	7
CWIP ⓘ	3	11	18	34
Investments ⓘ	12	8	82	104
Inventories	3	3	5	9
Trade Receivables	8	16	22	26
Cash Equivalents ⓘ	1	0	10	360
Others Assets ⓘ	26	65	125	247
Total Assets ⓘ	55	112	286	834

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-24	-43	-19	-20
PBT ⓘ	1	2	2	5
Adjustment ⓘ	1	-2	-3	-10
Changes in Working Capital ⓘ	-25	-43	-18	-14
Tax Paid ⓘ	-0	-0	-1	-1
Cash Flow From Investing Activity ⓘ +	-10	-5	-57	-163
Capex	-0	-8	-19	-49
Net Investments	0	0	0	0
Others ⓘ	-10	3	-38	-114
Cash Flow From Financing Activity ⓘ +	34	47	87	533
Net Proceeds from Shares ⓘ	24	3	37	536
Net Proceeds from Borrowing ⓘ	9	13	16	56
Interest Paid ⓘ	-1	-2	-3	-6
Dividend Paid ⓘ	0	0	0	0
Others ⓘ	1	33	37	-54
Net Cash Flow ⓘ	-0	-2	10	349

Financial Ratio

PARTICULARS	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	2.02	3.3	0.78	0.84
ROCE (%)	2.9	5.54	2.63	2.19
Asset Turnover Ratio	0.25	0.15	0.17	0.07
PAT to CFO Conversion(x)	-24	-43	-19	-5
Working Capital Days
Receivable Days	225.50	355.20	202.50	225.90
Inventory Days	80.40	90	41	62.40
Payable Days	269.20	325	151.10	253.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

1.90

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Senores Pharmaceuticals Ltd FAQs

The current trading price of Senores Pharmaceutic on 24-Jun-2026 16:59 is ₹1,275.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jun-2026 the market cap of Senores Pharmaceutic stood at ₹5,876 Cr

The latest P/E ratio of Senores Pharmaceutic as of 23-Jun-2026 is 290.2.

The latest P/B ratio of Senores Pharmaceutic as of 23-Jun-2026 is 7.84.

The 52-week high of Senores Pharmaceutic is ₹1,355.7 and the 52-week low is ₹522.9.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Senores Pharmaceutic is ₹106 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Senores Pharmaceuticals Ltd is a below average quality company.

The key valuation ratios of Senores Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Senores Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. The name of the Company was thereafter changed to ‘Senores Pharmaceuticals Limited’ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing it as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, it strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.

It leverages its R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Its focus on quality and its ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through its partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies.

Products of the company

Marketed Products

ANDA Products

Acetaminophen Butalbital and Acetaminophen Butalbital Caffeine
Chlorzoxazone
Diclofenac potassium
Ketorolac
Mexiletine Hydrochloride

Sourced Products

Awards, accreditations and recognitions

2022: Its subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘general’ section.
2022: Its Subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘B-lactum’ section.
2023: Its Subsidiary, RPPL, received the WHO-GMP certificate from the FDA in the ‘manufacturer’ category.
2023: Its Subsidiary, RPPL, received the GLP certificate from the FDA.
2024: The Atlanta Facility of its Subsidiary, Havix, was audited and approved by the USFDA.

History and milestones

2021: Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.
2021: Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.
2022: Started the domestic business with a launch of the critical care injectables.
2023: Acquired majority stake in Havix., making it a Subsidiary of the company
2023: Consolidated its presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a subsidiary of the company.
2024: Launched first CMO product in the US with Jubilant Cadista.

Senores Pharmaceuticals Ltd (SENORES)

Senores Pharmaceuticals Ltd (SENORES)

Senores Pharmaceuticals stock performance